All In Biotech

Drug Trial Radar · NCT07793929

A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

A Phase 1, Open Label, Parallel Group Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics of Ribupatide in Healthy Participants and in Participants Living With Severe Renal Impairment or End Stage Kidney Disease

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Sep 8, 2026

Primary completion

Feb 8, 2028

Study completion Feb 8, 2028

Sponsor

Lead sponsor
KaileraIndustry
Sponsor type
Industry
First posted
Aug 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection compared with participants with normal renal function.

Conditions

  • End Stage Renal Disease
  • Renal Impairment
  • Obesity
  • Overweight

Interventions

  • RibupatideDrug

    SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of RibupatideTime frame: Predose up to 816 hours postdose on Day 35
  2. Area Under Concentration Time Curve From Time Zero to Time of the Last Measurable Concentration (AUC0-t) of RibupatideTime frame: Predose up to 816 hours postdose on Day 35
  3. Area Under Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of RibupatideTime frame: Predose up to 816 hours postdose on Day 35

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kailera Clinical Site

    Orlando, Florida · Recruiting

  • Kailera Clinical Site

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.